Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 7/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671550 | 0.88 | EPHX2 (0.39) | EPHX2NR1H4RIPK1PTGESDPP4 | |
| SCHEMBL1671130 | 0.88 | EPHX2 (0.40) | EPHX2NR1H4RIPK1PTGESDPP4 | |
| SCHEMBL15167801 | 0.86 | RIPK1 (0.43) | EPHX2NR1H4RIPK1BDKRB1DPP4 | |
| SCHEMBL15169811 | 0.85 | RIPK1 (0.42) | EPHX2NR1H4RIPK1PTGESBDKRB1 | |
| SCHEMBL1671579 | 0.84 | PDK1 (0.38) | RIPK1PTGESBDKRB1KDM4EALDH1A1 | |
| SCHEMBL12799942 | 0.81 | EPHX2 (0.39) | EPHX2NR1H4RIPK1PTGESDPP4 | |
| SCHEMBL15170275 | 0.80 | IDO1 (0.41) | EPHX2NR1H4PTGESKDM4EALDH1A1 | |
| SCHEMBL15169717 | 0.79 | PTGES (0.44) | PTGES | |
| SCHEMBL15540907 | 0.76 | CA1 (0.39) | EPHX2NR1H4RIPK1PTGES | |
| SCHEMBL9898570 | 0.76 | EPHX2 (0.39) | EPHX2NR1H4RIPK1PTGESPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | EPHX2 127/4885NR1H4 248/4885RIPK1 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.